Multidrug Resistance Protein 1 Inhibitors To Sensitise Cancers To Chemotherapy
Funder
National Health and Medical Research Council
Funding Amount
$840,166.00
Summary
Multidrug resistance protein 1 (MRP1) is often present at high levels in cancer cells, where it pumps chemotherapy drugs back out, causing drug resistance. Inhibitors that block MRP1 would increase the effectiveness of chemotherapy. We have developed MRP1 inhibitors with promising activity in cancer cells and mouse tumours and will now develop these inhibitors for clinical application and commercialisation.
Identification Of Germline Variation That Predicts Progression Free Survival Following Chemotherapy For Advanced Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$633,156.00
Summary
Women diagnosed with ovarian cancer typically undergo surgery, followed by chemotherapy. However, the efficacy of chemotherapy varies widely, with some women responding well, whilst others are exposed to the toxic effects of a treatment that does them little good. We aim to identify the genes which explain why there are differences in response. This will lead to more individualised chemotherapy and improved outcomes for women with ovarian cancer.
An International Clinical Trial To Evaluate New Therapies To Improve Survival Of Children With Relapsed Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$1,567,500.00
Summary
Children who relapse with childhood leukaemia have only a 50% chance of being alive after 5 years. We will participate in a new international trial involving most European and all Australian and New Zealand childhood oncology centres, to test the effectiveness of promising new treatments and to perform biological studies which should enable doctors in future to pick the best treatment for each of these patients.